Press Release

NeoGenomics Schedules its Q4 2014 and Full Year 2014 Earnings Release for February 24, 2015

NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014

NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program

NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014

NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia

NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling

NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer

NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients